Citation Impact
Citing Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome
2009
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
2016
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
2014
Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes
2016
Corticotroph Pituitary Carcinoma: Case Report and Literature Review
2001
Future directions for peptide therapeutics development
2013
Cushing's syndrome
2015 Standout
A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
2012
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
2015
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
2014
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Coronavirus envelope protein: current knowledge
2019 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Type 2 diabetes
2017 Standout
Corticotroph carcinoma of the pituitary: a clinicopathological study
2002
Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
2014
The Future of Peptide‐based Drugs
2012 Standout
Peptide therapeutics: current status and future directions
2014 Standout
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
What We Talk About When We Talk About Fat
2014 Standout
G protein-coupled receptors as targets for anti-diabetic therapeutics
2016
Type 2 diabetes mellitus
2015 Standout
Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
2017
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
2016
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Use of Heart Rate Reserve and Rating of Perceived Exertion to Prescribe Exercise Intensity in Diabetic Autonomic Neuropathy
2003
Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: A systematic review and mixed‐treatment comparison analysis
2016
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
The Current State of Peptide Drug Discovery: Back to the Future?
2017
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
2016
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)
2013
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
2017
New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes
2016
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Targeting orphan G protein‐coupled receptors for the treatment of diabetes and its complications: C‐peptide andGPR 146
2016
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
2017
Novel Agents for the Treatment of Type 2 Diabetes
2014
Diabetic Kidney Disease
2017 Standout
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
2021
Versatile Peptide C-Terminal Functionalization via a Computationally Engineered Peptide Amidase
2016 StandoutNobel
GLP-1 receptor agonists: a review of head-to-head clinical studies
2014
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
2014
Mechanisms of Diabetic Complications
2013 Standout
Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
2017
Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association
2016 Standout
Implications of nonshivering thermogenesis for energy balance regulation in humans
2011
Diabetic Autonomic Neuropathy
2003 Standout
Diabetic Cardiomyopathy: Evidence, Mechanisms, and Therapeutic Implications
2004
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
2017
Works of P. Miossec being referenced
Adrenocorticotropin-producing pituitary carcinoma with liver metastasis
1997
Influence of parasympatheitc dysfunction and hyperinsulinemia on the hemodynamic response to an isometric exercise in non—insulin-dependent diabetic patients
1998
Glucose-induced thermogenesis, inhibition of lipid oxidation rate and autonomic dysfunction in non-diabetic obese women
1998
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
2014
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
2014
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
2013
Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme
2014
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
2012
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
2013
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin
2013